Fig. 3

CS treatment reduces Aβ-pathology in male E3FAD mice. Effect of CS treatment on Aβ-relevant pathology. VC, vehicle control. A Representative images of Aβ immunostaining (MOAB-2) in sagittal sections. Scale bar: 100 μm. B Quantification of % area covered by Aβ in the cortex by IHC. CS treatment reduced Aβ deposition in male E3FAD mice (p = 0.0194). C Representative images of Thio-S staining for amyloid deposition in sagittal sections. Scale bar: 100 μm. D Quantification of % area Thio-S coverage in the cortex. CS treatment reduced amyloid deposition in male E3FAD mice (p = 0.0002) and male E4FAD mice (p = 0.0495). Aβ levels were measured in TBS (soluble) and formic acid (insoluble) cortical extracts by ELISA. E Insoluble Aβ42 levels were reduced with CS treatment in male E3FAD mice (p = 0.0295). F Soluble oAβ levels were reduced in male E3FAD mice (p = 0.0244) and increased in female E4FAD mice (p = 0.0337) All biochemical experiments were conducted in the cortex. Data are expressed as mean ± SEM (Biochem, n = 7–12; IHC, n = 6–7), analyzed by t-test, *: p < 0.05 CS vs. VC. All data is from the same cohort of mice; the n’s differ because of study design, technical issues, and outlier tests